Tumor RNA Transfected Dendritic Cell Vaccines

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.

Key facts

Study ID

NCT00108264

Run by

US Department of Veterans Affairs

Expected to finish

2005-09-01

Last updated by the study team

2009-01-21

Who can join

Age: 10 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a histologically confirmed diagnosis of metastatic prostate cancer stages D1 - D3 are eligible for this study.
• They must not have a history of autoimmune disease, serious intercurrent chronic or acute illness, pulmonary disease, active hepatitis, serologic evidence for HIV, or be receiving corticosteroid or immunosuppressive therapy.

You may not qualify if…

• Patients will be excluded from the study if they have received chemotherapy or other forms of immunotherapy in the 6 weeks prior to study entry.

Where it is running

• Durham VA Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.